Visit https://www.peervoice.com/KKY860 to view the entire programme with slides. After completing “The Impact of Earlier Diagnosis and Timelier Treatment of Primary Hyperoxaluria Type 1”, participants will be able to: Describe the pathological processes of primary hyperoxaluria type 1 (PH1) that lead to end-stage renal disease; Recognise key signs and signals in patients with PH1 and the need for early diagnosis; and Discuss current management strategies for PH1 and the emerging pharmacological therapy.

Visit https://www.peervoice.com/QTK860 to view the entire programme with slides. After completing “SGLT2 Inhibition for HF: Evidence From Virtual Scientific Sessions 2020”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with heart failure (HF); Analyse clinical evidence for safety and efficacy of medical therapy such as SGLT2 inhibitors in patients with HF; and Describe the potential clinical implications of novel strategies on outcomes in HF.

Visit https://www.peervoice.com/AAE860 to view the entire programme with slides. After completing “A Look at Emerging SMA Outcomes: Highlights of WMS 2020”, participants will be able to: Describe the natural history of spinal muscular atrophy (SMA) and current unmet needs; Summarise the clinical implications of emerging treatment options and paradigms within the current standard of care; Establish treatment expectations with patients and caregivers, based on relevant patient- and disease-related factors, for patients with SMA; Describe the pathogenesis of SMA in terms of potential therapeutic targets; Review current progress in terms of diagnosis and management; and Analyse clinical evidence for novel therapeutic targets in terms of outcomes and safety.

Visit https://www.peervoice.com/JDW860 to view the entire programme with slides. After completing “Prevention and Acute Management of Migraine: Updates From London”, participants will be able to: Assess recent clinical data for new and emerging therapies for the prevention and acute management of migraine; Summarise what the latest data add to previously published data; and Illustrate how these data may inform treatment strategies for patients who suffer from migraine.

Visit https://www.peervoice.com/YPT860 to view the entire programme with slides. After completing “Novel Strategies for Chronic Kidney Disease: New Data, New Paradigm?”, participants will be able to: Summarise key finding from a published study evaluating an SGLT2 inhibitor for the management of CKD; Discuss the strengths and limitations of this study in light of current practices for the management of CKD; and Describe the impact of these data on clinical practice within the context of current and future treatment paradigms for CKD with or without diabetes.

Visit https://www.peervoice.com/XKS860 to view the entire programme with slides. After completing “Managing Complexity in Atopic Dermatitis: What Can We Learn From the Real World?”, participants will be able to: Understand the evolution of treatment targets and movement toward individualised treatment of moderate-to-severe atopic dermatitis (AD); Explore how real-world data can help bridge the gap between clinical trials and clinical practice; and Implement approaches to managing patients with complex cases of moderate-to-severe AD.

Visit https://www.peervoice.com/BSU860 to view the entire programme with slides. After completing “Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights of Kidney Week 2020”, participants will be able to: Describe key safety and efficacy data on SGLT2 inhibition for the management of chronic kidney disease (CKD); Summarise what the latest data on SGLT2 inhibition add to the current treatment algorithm for CKD; and Discuss the clinical implications of SGLT2 inhibition in the context of managing patients with CKD.

Visit https://www.peervoice.com/QBR860 to view the entire programme with slides. After completing “Optimising Treatment Outcomes in SJIA and AOSD”, participants will be able to: Describe systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still's disease (AOSD) as a continuum of auto-inflammatory Still’s disease; Discuss the biphasic model of SJIA and its implications for management; and Apply a treat-to-target approach in clinical practice.

Visit https://www.peervoice.com/NAK860 to view the entire programme with slides. After completing “Modern Management of Chronic Kidney Disease: A Look to the Future”, participants will be able to: Explain the rationale for novel therapies for the management of chronic kidney disease (CKD); Evaluate the safety and efficacy of recent clinical data for managing CKD, focusing on novel therapies; and Analyse the clinical implications of emerging evidence for managing CKD.

Visit https://www.peervoice.com/EQD860 to view the entire programme with slides. After completing “Practice Challenges in Advanced EGFR-Mutant NSCLC: Clarifying First-Line Strategies”, participants will be able to: Evaluate recent clinical data for current first-line treatment options in patients with advanced EGFR-mutant NSCLC, within the context of long-term care; Discuss strategies and options for managing specific challenges that can impact first-line treatment selection in patients with advanced EGFR-mutant NSCLC; and Formulate optimal treatment strategies that maximise outcomes in patients with advanced EGFR-mutant NSCLC.